

ALASKA MEDICAID
Prior Authorization Criteria

**Uptravi™
(sekexipag)**

FDA INDICATIONS AND USAGE¹

Uptravi™ is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression and reduce the risk of hospitalization.

APPROVAL CRITERIA^{1,2,3}

1. Patient's age is \geq 18 years of age; **AND**
2. Prescribed by or in consultation with a cardiologist or pulmonologist; **AND**
3. The diagnosis of pulmonary arterial hypertension (PAH, WHO Group 1) as confirmed by right heart catheterization; **AND**
4. Trial and failure, contraindication, or intolerance to oral therapies for PAH from at least 2 different categories, each for at least 60 days
 - a. phosphodiesterase-5 enzyme inhibitor
 - b. endothelin receptor antagonist (if not pregnant)
 - c. guanylate cyclase stimulator; **AND**
5. Patient is not currently taking and will not be taking together with a prostanoid/prostacyclin analogue

DENIAL CRITERIA¹

1. Failure to meet approval criteria; **OR**
2. Concomitant use with strong CYP2C8 inhibitors (e.g. gemfibrozil) contraindicated without provider attestation that the risks of treatment are outweighed by the benefits

CAUTIONS¹

- Monitor for pulmonary edema in patients with PVOD (pulmonary veno-occlusive disease)

DURATION OF APPROVAL

- Initial Approval: 6 months
 - Reauthorization 12 months with chart notes indicating the patient has shown positive clinical response to Uptravi™ treatment

ALASKA MEDICAID
Prior Authorization Criteria

QUANTITY LIMIT¹

#60 tablets max per 30 days up to 3200 mcg/day oral **OR**
#60 vials max per 30 days up to 3600 mcg/day IV: HCPCS J3490

REFERENCES / FOOTNOTES:

1. Uptravi™ [prescribing information]. Actelion Pharmaceuticals US, Inc. South San Francisco, CA.
2. Sitbon O, Channick R, et al; Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2015; 373:2522-2533
3. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults. Update of the CHEST guideline and Expert Panel Report. CHEST. 2019;155(3):565-586
4. Hopkins, W., and Rubin, L. (2022). Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy. In J. Mandel(Ed.), *UpToDate*. Retrieved Dec 20, 2022 from <https://www.uptodate.com/contents/treatment-of-pulmonary-arterial-hypertension-group-1-in-adults-pulmonary-hypertension-specific-therapy#!>